The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Tenosynovial giant cell tumors are a rare, locally aggressive neoplasm that is driven by an overexpression of colony-stimulating factor 1 (CSF1), a genetic anomaly which secretes a protein into the ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, safety, and impact on patient quality of life.

Source Reference: Gelderblom H, et al "Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" Lancet ...

BioWorld Content on 'tenosynovial giant cell tumors'Synox Therapeutics Ltd. has raised $75 million in a series B round to fund phase III development of emactuzumab, an antibody in-licensed from Roche ...

Among the 7MM, the United States had the highest prevalence of tenosynovial giant cell tumor, accounting for approximately 45% of total cases. In 2023, localized TGCT in the U.S. was most commonly ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

From The New England Journal of Medicine, Tap W, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor, Volume 373, Pages 428-437.

An investigational drug, PLX3397 (Plexxikon, Daiichi Sankyo), has shown prolonged tumor regression in patients with tenosynovial giant cell tumor (TGCT), a rare disorder of the joints that leaves ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT).

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...